Zobrazeno 1 - 10
of 227
pro vyhledávání: '"Mancuso FM"'
Autor:
Frigola, J, Navarro, A, Carbonell, C, Callejo, A, Iranzo, P, Cedres, S, Martinez-Marti, A, Pardo, N, Saoudi-Gonzalez, N, Martinez, D, Jimenez, J, Sansano, I, Mancuso, FM, Nuciforo, P, Montuenga, LM, Sanchez-Cespedes, M, Prat, A, Vivancos, A, Felip, E, Amat, R
Publikováno v:
Molecular Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Immunotherapy has transformed advanced non-small cell lung cancer (NSCLC) treatment strategies and has led to unprecedented long-lasting responses in some patients. However, the molecular determinants driving these long-term responses remain elusive.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::0fca44846935ed057f4df72638a00fca
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4747
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4747
Autor:
Élez E; Colorectal Cancer Program, Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Mulet-Margalef N; Colorectal Cancer Program, Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.; Colorectal Cancer Unit, Medical Oncology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain., Sanso M; Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.; Genomics for Precision Oncology Laboratory, Fundació Institut d'Investigació Sanitària Illes Balears (IdISBa), 07120 Palma de Mallorca, Spain., Ruiz-Pace F; Oncology Data Science Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Mancuso FM; Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.; Research and Development Department, Universal Diagnostics S.L., 41013 Sevilla, Spain., Comas R; Oncology Data Science Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Ros J; Colorectal Cancer Program, Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.; Departament of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, 81100 Naples, Italy., Argilés G; Colorectal Cancer Program, Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Martini G; Colorectal Cancer Program, Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.; Departament of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, 81100 Naples, Italy., Sanz-Garcia E; Colorectal Cancer Program, Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Baraibar I; Colorectal Cancer Program, Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Salvà F; Colorectal Cancer Program, Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Noguerido A; Colorectal Cancer Program, Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Cuadra-Urteaga JL; Colorectal Cancer Program, Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.; Medical Oncology, IOB-Hospital Quirón, 08023 Barcelona, Spain., Fasani R; Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Garcia A; Colorectal Cancer Program, Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Jimenez J; Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Aguilar S; Molecular Prescreening Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Landolfi S; Department of Pathology, Vall d'Hebron University Hospital, 08035 Barcelona, Spain., Hernández-Losa J; Department of Pathology, Vall d'Hebron University Hospital, 08035 Barcelona, Spain., Braña I; Medical Oncology Department, Research Unit for Molecular Therapy of Cancer, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Nuciforo P; Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Dienstmann R; Oncology Data Science Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Tabernero J; Colorectal Cancer Program, Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Salazar R; Colorectal Cancer Unit, Medical Oncology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.; Medical Oncology Department, Catalan Institute of Oncology, Oncobell Program (IDIBELL), CIBERONC, L'Hospitalet de Llobregat, 08908 Barcelona, Spain., Vivancos A; Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
Publikováno v:
International journal of molecular sciences [Int J Mol Sci] 2022 Dec 21; Vol. 24 (1). Date of Electronic Publication: 2022 Dec 21.
Autor:
Capdevila, J, Arques, O, Mora, JRH, Matito, J, Caratu, G, Mancuso, FM, Landolfi, S, Barriuso, J, Jimenez-Fonseca, P, Lopez, CL, Garcia-Carbonero, R, Hernando, J, Matos, I, Paolo, N, Hernandez-Losa, J, Esteller, M, Martinez-Cardus, A, Tabernero, J, Vivancos, A, Palmer, HG
Publikováno v:
Clinical Cancer Research
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Universidad de Alicante (UA)
r-IGTP: Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Institut de Recerca Germans Trias i Pujol (IGTP)
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Universidad de Alicante (UA)
r-IGTP: Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Institut de Recerca Germans Trias i Pujol (IGTP)
Purpose: The limited knowledge of the molecular alterations that characterize poorly differentiated neuroendocrine carcinomas has limited the clinical development of targeted agents directed to driver mutations. Here we aim to identify new molecular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::21b91f35b909391c7cf8d074a0c8eb79
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1223
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1223
Autor:
Martinez-Marti A; Department of Medical Oncology, Vall d'Hebron University Hospital (VHUH), Barcelona, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Autonomous University of Barcelona (UAB), Barcelona, Spain., Felip E; Department of Medical Oncology, Vall d'Hebron University Hospital (VHUH), Barcelona, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; University of Vic (UVIC) Central University of Catalonia (UCC), Barcelona, Spain., Mancuso FM; Cancer Genomics Group, VHIO, Barcelona, Spain., Caratú G; Cancer Genomics Group, VHIO, Barcelona, Spain., Matito J; Cancer Genomics Group, VHIO, Barcelona, Spain., Nuciforo P; Molecular Oncology Group, VHIO, Barcelona, Spain., Sansano I; Pathology Department, VHUH, Barcelona, Spain., Diaz-Mejia N; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Cedrés S; Department of Medical Oncology, Vall d'Hebron University Hospital (VHUH), Barcelona, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Callejo A; Department of Medical Oncology, Vall d'Hebron University Hospital (VHUH), Barcelona, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Iranzo P; Department of Medical Oncology, Vall d'Hebron University Hospital (VHUH), Barcelona, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Pardo N; Department of Medical Oncology, Vall d'Hebron University Hospital (VHUH), Barcelona, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Miquel JM; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Navarro A; Department of Medical Oncology, Vall d'Hebron University Hospital (VHUH), Barcelona, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Vivancos A; Cancer Genomics Group, VHIO, Barcelona, Spain., Sansó M; Cancer Genomics Group, VHIO, Barcelona, Spain. miriam.sanso@ssib.es.; Balearic Islands Health Research Institute (IdISBa), Palma de Mallorca, Spain. miriam.sanso@ssib.es.; Genomics for Precision Oncology Group, Health Research Institute of the Balearic Islands (IdISBa), University Hospital Son Espases (HUSE), Palma de Mallorca, Spain. miriam.sanso@ssib.es.
Publikováno v:
British journal of cancer [Br J Cancer] 2021 Nov; Vol. 125 (11), pp. 1561-1569. Date of Electronic Publication: 2021 Oct 01.
Autor:
Frigola J; Thoracic Cancers Translational Genomics Unit, Hebron Institute of Oncology (VHIO), Vall d, Barcelona, Spain., Navarro A; Oncology Department, Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Carbonell C; Thoracic Cancers Translational Genomics Unit, Hebron Institute of Oncology (VHIO), Vall d, Barcelona, Spain., Callejo A; Oncology Department, Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Iranzo P; Oncology Department, Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Cedrés S; Oncology Department, Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Martinez-Marti A; Oncology Department, Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Pardo N; Oncology Department, Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Saoudi-Gonzalez N; Oncology Department, Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Martinez D; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain., Jimenez J; Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Sansano I; Pathology Unit, Vall d'Hebron University Hospital, Barcelona, Spain., Mancuso FM; Cancer Genomics Laboratory, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Nuciforo P; Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Montuenga LM; Program in Solid Tumors, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Navarra Health Research Institute (IDISNA), Pamplona, Spain., Sánchez-Cespedes M; Cancer Genetics Group, Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias i Pujol, Badalona, Barcelona, Spain., Prat A; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain., Vivancos A; Cancer Genomics Laboratory, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Felip E; Thoracic Cancers Translational Genomics Unit, Hebron Institute of Oncology (VHIO), Vall d, Barcelona, Spain.; Oncology Department, Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Amat R; Thoracic Cancers Translational Genomics Unit, Hebron Institute of Oncology (VHIO), Vall d, Barcelona, Spain.
Publikováno v:
Molecular oncology [Mol Oncol] 2021 Apr; Vol. 15 (4), pp. 887-900. Date of Electronic Publication: 2021 Jan 06.
Autor:
Ogbah Z; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Mancuso FM; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Vivancos A; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. avivancos@vhio.net.
Publikováno v:
Methods in molecular biology (Clifton, N.J.) [Methods Mol Biol] 2021; Vol. 2318, pp. 321-336.
Autor:
Capdevila J; Department of Medical Oncology, Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona (UAB), CIBERONC, Barcelona, Spain., Arqués O; Stem Cells and Cancer Laboratory, Vall d'Hebron Institute of Oncology (VHIO), CIBERONC, Barcelona, Spain., Hernández Mora JR; Cancer Epigenetics Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain., Matito J; Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Caratù G; Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Mancuso FM; Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Landolfi S; Department of Pathology, Vall d'Hebron University Hospital (HUVH), Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain., Barriuso J; Department of Medical Oncology, European Neuroendocrine Tumor Society (ENETS) Centre of Excellence, The Christie NHS Foundation Trust, Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom., Jimenez-Fonseca P; Department of Medical Oncology, Central de Asturias University Hospital, Oviedo, Spain., Lopez Lopez C; Department of Medical Oncology, Marques de Valdecilla University Hospital, Santander, Spain., Garcia-Carbonero R; Department of Medical Oncology, Doce de Octubre University Hospital, Instituto de Investigacion Hospital 12 de Octubre (i+12), Centro Nacional de Investigacion Oncologica (CNIO), CIBERONC, Universidad Complutense de Madrid (UCM), Madrid, Spain., Hernando J; Department of Medical Oncology, Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona (UAB), CIBERONC, Barcelona, Spain., Matos I; Early Clinical Drug Development Group, Medical Oncology Department, Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain., Paolo N; Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Hernández-Losa J; Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Esteller M; Cancer Epigenetics Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain., Martínez-Cardús A; Cancer Epigenetics Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain., Tabernero J; Department of Medical Oncology, Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona (UAB), CIBERONC, Barcelona, Spain., Vivancos A; Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. hgpalmer@vhio.net avivancos@vhio.net., Palmer HG; Stem Cells and Cancer Laboratory, Vall d'Hebron Institute of Oncology (VHIO), CIBERONC, Barcelona, Spain. hgpalmer@vhio.net avivancos@vhio.net.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Feb 15; Vol. 26 (4), pp. 902-909. Date of Electronic Publication: 2019 Oct 31.
Autor:
Serrano C; Medical Oncology Department, Vall d'Hebron University Hospital, P. Vall d'Hebron 119, 08035, Barcelona, Spain. cserrano@vhio.net.; Preclinical Research Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain. cserrano@vhio.net., Vivancos A; Cancer Genomics Group, |Vall d'Hebron Institute of Oncology, Natzaret 115, 08035, Barcelona, Spain. avivancos@vhio.net., López-Pousa A; Medical Oncology, Sant Pau University Hospital, Barcelona, Spain., Matito J; Cancer Genomics Group, |Vall d'Hebron Institute of Oncology, Natzaret 115, 08035, Barcelona, Spain., Mancuso FM; Cancer Genomics Group, |Vall d'Hebron Institute of Oncology, Natzaret 115, 08035, Barcelona, Spain., Valverde C; Medical Oncology Department, Vall d'Hebron University Hospital, P. Vall d'Hebron 119, 08035, Barcelona, Spain., Quiroga S; Radiology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Landolfi S; Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Castro S; Surgical Oncology Division, Vall d'Hebron University Hospital, Barcelona, Spain., Dopazo C; Surgical Oncology Division, Vall d'Hebron University Hospital, Barcelona, Spain., Sebio A; Medical Oncology, Sant Pau University Hospital, Barcelona, Spain., Virgili AC; Medical Oncology, Sant Pau University Hospital, Barcelona, Spain., Menso MM; Radiology Department, Sant Pau University Hospital, Barcelona, Spain., Martín-Broto J; Medical Oncology, Virgen del Rocío Hospital, Sevilla, Spain., Sansó M; Cancer Genomics Group, |Vall d'Hebron Institute of Oncology, Natzaret 115, 08035, Barcelona, Spain., García-Valverde A; Preclinical Research Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Rosell J; Preclinical Research Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Fletcher JA; Pathology Department, Brigham and Women's Hospital/Harvard Medical School, Boston, USA., George S; Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, USA., Carles J; Medical Oncology Department, Vall d'Hebron University Hospital, P. Vall d'Hebron 119, 08035, Barcelona, Spain., Arribas J; Preclinical Research Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.
Publikováno v:
BMC cancer [BMC Cancer] 2020 Feb 05; Vol. 20 (1), pp. 99. Date of Electronic Publication: 2020 Feb 05.
Autor:
Capdevila J; Department of Medical Oncology, Vall Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Autonomous University of Barcelona (UAB), Barcelona, Spain. jacapdevila@vhebron.net., Matos I; Department of Medical Oncology, Vall Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Autonomous University of Barcelona (UAB), Barcelona, Spain., Mancuso FM; Cancer Genomic Group, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain., Iglesias C; Department of Pathology, Vall Hebron University Hospital, Autonomous University of Barcelona (UAB), Barcelona, Spain., Nuciforo P; Molecular Oncology Group, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain., Zafon C; Diabetes and Metabolism Research Unit (VHIR) and Department of Endocrinology, Vall Hebron University Hospital and Autonomous University of Barcelona (UAB), Barcelona, Spain., Palmer HG; Stem Cells and Cancer Group, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain., Ogbah Z; Cancer Genomic Group, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain., Muiños L; Cancer Genomic Group, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain., Hernando J; Department of Medical Oncology, Vall Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Autonomous University of Barcelona (UAB), Barcelona, Spain., Villacampa G; Oncology Data Science Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Peña CE; Bayer HealthCare Pharmaceuticals Inc., Whippany, New Jersey., Tabernero J; Department of Medical Oncology, Vall Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Autonomous University of Barcelona (UAB), Barcelona, Spain., Brose MS; Department of Otorhinolaryngology, Head and Neck Surgery, and Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania., Schlumberger M; Gustave Roussy and University Paris Sud, Villejuif, France., Vivancos A; Cancer Genomic Group, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2020 Jan; Vol. 19 (1), pp. 312-317. Date of Electronic Publication: 2019 Sep 20.
Autor:
Capdevila J, Mayor R, Mancuso FM, Iglesias C, Caratú G, Matos I, Zafón C, Hernando J, Petit A, Nuciforo P, Cameselle-Teijeiro JM, Álvarez CV, Recio JA, Tabernero J, Matias-Guiu X, Vivancos A, Seoane J
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2019 Nov 01; Vol. 30 (11), pp. 1843.